Join Paul Fitzpatrick and the Boehringer Ingelheim team for a look at the future of our swine business. Paul discusses how strategic investments in our people, science, and innovation will help us continue to grow and deliver value to our customers. He shares our goal to transform lives, both human and animal, and emphasises our commitment to remaining the #1 swine business in the region.
Dr. Gustavo Silva, an expert in veterinary epidemiology from Iowa State University, takes us through a comprehensive overview of Porcine Circovirus Type 2 (PCV2) and its associated diseases. He discusses the virus's prevalence, transmission, and the evolution of its genotypes over time. Dr. Silva highlights the importance of vaccination and proper diagnostics, sharing valuable insights on how PCV2 infections are managed in the US and globally. He also touches on PCV3, clarifying its role in swine health and its relationship with other pathogens.
Dr. Steven McOrist, a renowned pig health consultant, presents the results of a head-to-head trial comparing two commercial PCV2 vaccines under Australian conditions. He details the trial's design and findings, revealing that while both vaccines effectively control the virus, one led to significant improvements in pig performance. The results show a measurable difference in approachability after vaccination, a reduction in the number of slow-growing pigs, and an improved average daily weight gain. Dr. McOrist's presentation highlights how these factors contribute to earlier market days and a better overall return on investment for farmers.
Economist Lance Mulberry provides an in-depth analysis of the economic results of the recent Australian PCV vaccine trial. He emphasizes that while a 7-gram difference in average daily gain might seem small, the real impact lies in the 8% reduction in slow-growing pigs.
